🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. eythrocytapheresis

    Atrium Therapeutics

    Pre Operative Autologous Donation

    phase 3 other completed

    1 trial

  2. filgrastim

    Hospital Authority, Hong Kong

    Brain and Central Nervous System Tumors

    phase 3 mab completed

    2 trials

  3. gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  4. guanfacine

    Ultragenyx UK Limited

    Tourette Syndrome

    phase 3 small molecule completed

    1 trial

  5. hydroxychloroquine (Z0188)

    Sanofi Pasteur

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  6. individual lactation counseling and educational material

    Hospital Authority, Hong Kong

    Breastfeeding

    phase 3 other completed

    1 trial

  7. lactose monohydrate - 100,00 mg/tablet cellulose microcrystalline - 95,60 mg/tablet Croscarmellose sodium - 2,00 mg/tablet Magnesium stearate - 2,40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON, Asmenol, 10 mg, tabletki powlekane

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  8. lomustine

    United Therapeutics Europe Ltd

    Brain and Central Nervous System Tumors

    phase 3 small molecule completed

    1 trial

  9. mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  10. nomacopan (rVA576)

    Akari Therapeutics Plc

    Bullous Pemphigoid

    phase 3 small molecule terminated

    1 trial

  11. one percent ultrasound power in CMICS

    Hospital Authority, Hong Kong

    Cataract

    phase 3 other active

    1 trial

  12. preoperative short-course radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 other terminated

    1 trial

  13. six courses of zanubrutinib, rituximab and lenalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  14. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Non 24 Hour Sleep Wake Disorder

    phase 3 small molecule active

    4 trials

  15. the Shouhui Tongbian Capsule

    The First People's Hospital of Lianyungang

    OIC

    phase 3 small molecule active

    1 trial

  16. three consecutive lots of EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  17. tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  18. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  19. volrustomig

    AstraZeneca

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  20. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial

  21. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  22. zodasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  23. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  24. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources